Skip to main content
OpenTrials
Completed

NCT Number: NCT03814993

taPentadol cLinical prAcTice IN belgiUM

Multicenter observational study to determine the long-term tolerability and analgesic effectiveness of oral tapentadol in patients suffering from severe pain syndromes, refractory to other strong opioids.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

AZ Monic, Antwerp, Belgium

Loading trial locations.

About this study

Tapentadol, a centrally acting analgesic. It is indicated in Europe "for the relief of moderate to severe acute pain in adults, which can be adequately managed only with opioid analgesics" (IR formulation/oral solution) and "for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics" (SR formulation). Tapentadol is reimbursed in Belgium since May 1, 2018. The reimbursement was obtained through an article 81 procedure (Chapter IV) which means that the reimbursement is currently restricted to the time frame of the contract and that during that period certain questions and uncertainties regarding the use of tapentadol in a Belgian setting need to be answered. In order to answer the questions raised by the Belgian Healthcare authorities, this study will be performed evaluating the application of oral tapentadol in routine clinical practice in Belgium. The study is conceived as a nation-wide multicentre prospective non-interventional trial. The primary endpoint and secondary endpoints of this study are guided by the questions that need to be answered during the course of the contract reimbursement, as established by the Belgian health authorities.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects should be capable of giving their informed consent;
  • Males and females, 18 years and older;
  • Patients suffering from severe pain;
  • Pain symptoms refractory to strong opioids (in previous treatment);
  • Due to side effects
  • Due to insufficient analgesic effectiveness
  • Due to opioid induced hyperalgesia.

Exclusion criteria

  • Severe renal and/or hepatic insufficiency;
  • Known and/or strong suspicion of allergy to tapentadol;
  • Previous treatment with tapentadol;
  • Presence of any condition for which tapentadol is contraindicated as per its approved labelling information in Belgium;
  • The patient has no access to a mobile phone and web browser. During the study, an online system is used to receive messages (SMS and e-mail) for the completing of the online assessments (through web browser).

Treatment and study plan

Primary outcomes

  1. Difference in occurrence of gastrointestinal side effects (nausea, vomiting and constipation) between baseline and week 15

    Time frame: baseline - week 15

    Differences in occurence of the PRO-CTCAE items: Nausea, vomiting and constipation

Secondary outcomes

  1. Difference in frequency, severity and interference of selected side effects (dizziness, fatigue, itching, headache, dry mouth, nausea, vomiting, constipation) from baseline to week 52

    Time frame: baseline - week 52

    Difference in frequency, severity and interference of selected PRO-CTCAE items

  2. Change From Baseline in Pain Scores on the Numeric Rating Scale baseline to different time points during long-term follow-up

    Time frame: baseline - week 52

    Reduction in pain intensity numeric rating scale (PI-NRS). Scale: 0 = no pain and 10 = worst possible pain

  3. Change of health-related quality of life from baseline to different time points during long-term follow-up

    Time frame: baseline - week 52

    Change of healt-related quality of life measured by EQ-5D-5L (monthly evaluation)

  4. Change of health-related quality of life from baseline to different time points during long-term follow-up

    Time frame: baseline - week 52

    Change of healt-related quality of life measured SF-36 (monthly evaluation)

  5. Change of functional status of the patient from baseline to different time points during long-term follow-up

    Time frame: baseline - week 52

    Change of functional status measured by GPE-DV (monthly evaluation)

  6. Change of functional status of the patient from baseline to different time points during long-term follow-up

    Time frame: baseline - week 52

    Change of functional status measured by impact pain on functioning (Interference-BPI)

  7. Change of functional status of the patient from baseline to different time points during long-term follow-up

    Time frame: baseline - week 52

    Change of functional status measured by SF-36 (monthly evaluation)

  8. The occurrence of tolerance during oral tapentadol treatment from baseline to different time points during long-term follow-up

    Time frame: baseline - week 52

    Occurence of tolerance by the use of MQS-III questionnaire (weekly or monthly)

  9. The occurrence of tolerance during oral tapentadol treatment from baseline to different time points during long-term follow-up

    Time frame: baseline - week 52

    Occurence of tolerance by the use time-point of discontinuation of study drug

  10. Drug conversion rates from other strong opioids to oral tapentadol from baseline to different time points during long-term follow-up

    Time frame: baseline - week 52

    By the use of MQS-III questionnaire

Sponsors and collaborators

Lead sponsor

Dafne Balemans

Other

Collaborators

  • Grünenthal GmbH

Registry information

Official study title

Multicenter Observational Study to Determine the Long-term Tolerability and Analgesic Effectiveness of Oral Tapentadol in Patients Suffering From Severe Pain Syndromes, Refractory to Other Strong Opioids.

Acronym: PLATINUM

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Jan 24, 2019
Registry last updated
Feb 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.